Golimumab retention in patients with psoriatic arthritis and axial spondyloarthritis: evidence from up to a decade of follow-up
In this real-world study, a non-negligible retention of GOL is observed. The two diseases differ in the factors that appear to determine drug persistence.
Authors
- Mercedes Alperí (ORCID: https://orcid.org/0000-0002-8727-0876)
- Rubén Queiró (ORCID: https://orcid.org/0000-0002-8418-7145)
- Pablo González del Pozo (ORCID: https://orcid.org/0009-0000-4448-4690)
- Paula Álvarez (ORCID: https://orcid.org/0000-0001-9598-8768)
- Norma Calleja
- Arancha Gómez-Cosme
Institutions
- Universidad de Oviedo (ES)
- Hospital Universitario Central de Asturias (ES)
Publication Details
- Journal
- Expert Review of Clinical Pharmacology
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1080/17512433.2025.2508960
- Citations
- 1
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.67